Trial Profile
Phase II Study of Neo-adjuvant Chemoradiotherapy Using Infusional Gemcitabine Followed by Surgery for Locally Advanced (T3 and T4 or Node Positive) Rectal Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2022
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Capecitabine
- Indications Adenocarcinoma; Rectal cancer
- Focus Therapeutic Use
- 22 Jan 2022 Status changed from recruiting to completed as per results presented at the 2022 Gastrointestinal Cancers Symposium
- 22 Jan 2022 Results presented at the 2022 Gastrointestinal Cancers Symposium
- 05 Oct 2016 New trial record